6/29/23, 11:44 PM SOAP II Pathway Feedback Search Clinical Topics Home Studies SOAP II SOAP II Disease Sepsis and septic shock Trial question What is the role of dopamine as first-line vasopressor agent in patients with shock? Study design Multi-center Double blinded RCT Population Characteristics of study participants 43.0% female N = 1679 57.0% male 1679 patients (723 female, 956 male) Inclusion criteria: patients with shock Key exclusion criteria: age < 18 years; already received a vasopressor agent (dopamine, norepinephrine, epinephrine, or phenylephrine) for > 4 hours during the current episode of shock; serious arrhythmia, such as rapid AF (> 160 beats/min) or VT; or declared brain-dead Interventions N=858 dopamine (dose determined according to the patient's body weight, could be increased or decreased by 2 g/kg/min) N=821 norepinephrine (dose determined according to the patient's body weight, could be increased or decreased by 0.02 g/kg/min) https://web.pathway.md/studies/recScwrf3pouG7jpl 1/2 6/29/23, 11:44 PM SOAP II Pathway Primary outcome Death at 28 days 52.5 % 52.5 48.5 39.4 % 26.3 % 13.1 % No significant difference 0.0 % Dopamine Norepinephrine No significant difference in death at 28 days (52.5% vs. 48.5%; OR 1.17, 95% CI 0.97 to 1.42) Secondary outcomes Significant increase in required open-label norepinephrine therapy (26% vs. 20%; RR 1.3, 95% CI 0.53 to 2.07) Significant increase in open-label vasopressors not needed (12.6 vs. 14.2; MD 1.6, 95% CI 0.44 to 2.76) Safety outcomes Significant differences in arrhythmic events (24.1% vs. 12.4%, p < 0.001). Conclusion In patients with shock, dopamine was not superior to norepinephrine with respect to death at 28 days. Reference De Backer D, Biston P, Devriendt J et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010 Mar 4;362(9):779-89. Open reference URL https://web.pathway.md/studies/recScwrf3pouG7jpl 2/2